---
document_datetime: 2023-09-21 21:09:57
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imatinib-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: imatinib-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5996712
conversion_datetime: 2025-12-25 06:03:07.735183
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Imatinib Actavis

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                          | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0020              | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                  | 16/12/2021                                  |                                             | SmPC and PL                      |           |
| IB/0019              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 13/08/2020                                  | 20/08/2021                                  | SmPC and PL                      |           |

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |               | authorised         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|--------------------|
| IB/0018   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                         | 05/09/2019 | 27/08/2020    | SmPC and PL        |
| IB/0017/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product | 30/11/2018 | 11/01/2019 no | SmPC and PL longer |
| IB/0016   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by Medicinal                                                                                                                                                                                                                                                                                                                       | 05/04/2018 | 11/01/2019    | SmPC and PL        |

<div style=\"page-break-after: always\"></div>

|           | the MAH                                                                                                                                                                                                                                                                                                                                                                                                                  |            |               |                                                                                                                                                                                                                                                                                                |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0015    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                  | 09/11/2017 | 08/01/2018    | SmPC Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Imatinib Actavis in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. authorised |
| II/0013   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                              | 21/09/2017 | n/a           |                                                                                                                                                                                                                                                                                                |
| IB/0012   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                            | 10/05/2017 | n/a           | longer                                                                                                                                                                                                                                                                                         |
| IB/0014   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product                                                                                                                                                     | 21/04/2017 | 08/01/2018 no | SmPC, Labelling and PL                                                                                                                                                                                                                                                                         |
| IB/0011/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following Medicinal | 20/12/2016 | 24/04/2017    | SmPC and PL                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| IB/0010   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/05/2016 24/04/2017 SmPC, Labelling and authorised   |
| IB/0009   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/07/2015 02/06/2016 SmPC                             |
| IB/0008/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product | 01/06/2015 02/06/2016 SmPC, Labelling and PL no longer |
| IB/0006/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/11/2014 n/a                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                   |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| N/0005 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/10/2014 02/06/2016 PL                                                                                          |
| X/0003 | Line extension to add a new strength, 400mg hard capsule. In addition the MAH is adding the following indications already authorised for the reference product Glivec: - adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. - adult patients with relapsed or refractory Ph+ ALL as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRÎ± rearrangement. - the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. Annex I_2.(c) Change or addition of a new Medicinal product | 20/03/2014 12/06/2014 SmPC, Labelling and PL See Scientific Discussion: \"H-2594-VAR-X-03-en' no longer authorised |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0004   | strength/potency C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                         | 27/03/2014         | 12/06/2014    | SmPC, Labelling and PL authorised   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-------------------------------------|
| IB/0001/G | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product | 18/07/2013         | 12/06/2014 no | SmPC, Labelling and PL longer       |
| IAIN/0002 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes Medicinal                                                                                                          | 18/06/2013 product | 12/06/2014    | SmPC, Labelling and PL              |